bcr-abl oncoprotein

bcr-abl oncoprotein

A protein product of the fused BCR-ABLl oncogene produced by the Philadelphia chromosome, which plays a key role in initiating and maintaining leukaemia.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Imatinib is a 2-phenylaminopyrimidine compound that inhibits the BCR-ABL oncoprotein found in CML cells [12].
Chronic myeloid leukemia (CML) is a myeloproliferative disease that originates in an haemopoietic stem cell as a result of t (9; 22) translocation, giving rise to the Ph (Philadelphia chromosome) and Bcr-Abl oncoprotein. The disease starts in a chronic phase, but as a result of genomic instability, it progresses over time to the accelerated phase and then to blast crisis, becoming increasingly resistant to therapy.
Most importantly, the BCR-ABL oncoprotein provided, for the first time, a specific therapeutic target in hematologic malignancies.
The Bcr-Abl oncoprotein differs from the endogenous c-Abl protein in both its subcellular localization and its tyrosine kinase (TK) activity.